Department of Microbiology, College of Medicine, National Taiwan University, Taipei, 10051, Taiwan.
Ph.D. Program in Translational Medicine, National Taiwan University and Academia Sinica, Taipei, 10051, Taiwan.
Sci Rep. 2017 Jun 19;7(1):3842. doi: 10.1038/s41598-017-03385-6.
SMYD3 is a methyltransferase highly expressed in many types of cancer. It usually functions as an oncogenic protein to promote cell cycle, cell proliferation, and metastasis. Here, we show that SMYD3 modulates another hallmark of cancer, DNA repair, by stimulating transcription of genes involved in multiple steps of homologous recombination. Deficiency of SMYD3 induces DNA-damage hypersensitivity, decreases levels of repair foci, and leads to impairment of homologous recombination. Moreover, the regulation of homologous recombination-related genes is via the methylation of H3K4 at the target gene promoters. These data imply that, besides its reported oncogenic abilities, SMYD3 may maintain genome integrity by ensuring expression levels of HR proteins to cope with the high demand of restart of stalled replication forks in cancers.
SMYD3 是一种在多种癌症中高度表达的甲基转移酶。它通常作为致癌蛋白发挥作用,促进细胞周期、细胞增殖和转移。在这里,我们表明 SMYD3 通过刺激参与同源重组多个步骤的基因的转录来调节癌症的另一个标志,即 DNA 修复。SMYD3 的缺乏会诱导 DNA 损伤敏感性增加,降低修复焦点水平,并导致同源重组受损。此外,同源重组相关基因的调节是通过靶基因启动子上 H3K4 的甲基化来实现的。这些数据表明,除了其报道的致癌能力外,SMYD3 还可以通过确保 HR 蛋白的表达水平来维持基因组的完整性,以应对癌症中停滞复制叉重新启动的高需求。